Why we believe in Lexaria (CSE: LXX)
I read a brief article explaining the difference between bioavailability and bioactivity that is important in the case of Lexaria (CSE:LXX) (OTCQX: LXRP) and its DehydraTECH™ technology. Bioavailability refers to the amount and the speed at which the active drug or molecule is delivered to its intended destination. Bioactivity refers to the retention of the molecule’s functional pharmacological properties. I have known for some time the bioavailability characteristics of LXX’s technology is excellent delivering more molecules faster than competitive methods. In exchanging information with Chris Bunka, CEO and John Docherty, President, I learned in numerous tests with CBD, the expected pharmacological characteristics have been retained.
I find this comforting because in the three years I have been aware of this technology, every time it has been challenged, it has come through with flying colours. The testing that is currently underway with Altria is the most important challenge DehydraTECH™ has faced and success will be a strong influence on LXX’s fortunes over the next year or two. That’s why I’m supporting Bunka, Docherty and DehydraTECH™.